BAAM
NVCR icon

Baker Avenue Asset Management’s NovoCure NVCR Stock Holding History

Baker Avenue Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$118K Buy
+10,858
New +$136K ﹤0.01% 742
2023
Q1 		– Sell
-8
Closed -$587 – 1711
2022
Q4 		$587 Buy
+8
New +$602 ﹤0.01% 1262

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Baker Avenue Asset Management's NVCR Position: Q1 2026 in Review

Baker Avenue Asset Management opened a new position in NovoCure (NVCR) in Q1 2026: 10,858 shares worth $118K. The stake represents ﹤0.01% of the portfolio and ranks #742 among its holdings. This is a return to the name: Baker Avenue Asset Management previously reported a position in NVCR as recently as Q4 2022.

Baker Avenue Asset Management first reported a position in NVCR in Q4 2022 and has held it in 2 quarters since. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Baker Avenue Asset Management held 10,858 shares of NovoCure worth $118K as of Q1 2026.
  • NovoCure was a new Baker Avenue Asset Management position in Q1 2026.
  • NovoCure made up ﹤0.01% of Baker Avenue Asset Management's portfolio in Q1 2026, its #742 holding.
  • Baker Avenue Asset Management first reported a position in NovoCure in Q4 2022 and has held it in 2 quarters since.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Baker Avenue Asset Management's 13F filing for Q1 2026, filed 12 May 2026.